Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice-Reference-Cited by-同舟云学术

Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice

Published:2020-09 Issue:3 Volume:112 Page:248-259
ISSN:1591-951X
Container-title:Pathologica
language:
Short-container-title:Pathologica

Author:

Fassan Matteo,Scarpa Aldo,Remo Andrea,De Maglio Giovanna,Troncone Giancarlo,Marchetti Antonio,Doglioni Claudio,Ingravallo Giuseppe,Perrone Giuseppe,Parente Paola,Luchini Claudio,Mastracci Luca

Publisher

Siapec Servizi Srl

Subject

Pathology and Forensic Medicine

Reference112 articles.

1. Fassan M. Molecular diagnostics in pathology: time for a next-generation pathologist? Arch Pathol Lab Med 2018;142:313-20. https://doi.org/10.5858/arpa.2017-0269-RA

2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97. https://doi.org/10.1016/S0140-6736(10)61121-X

3. Pellino A, Riello E, Nappo F, et al. Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives. World J Gastroenterol 2019;25:5773-88. https://doi.org/10.3748/wjg.v25.i38.5773

4. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18:476-84. https://doi.org/10.1007/s10120-014-0402-y

5. Grillo F, Fassan M, Sarocchi F, et al. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol 2016;22:5879-87. https://doi.org/10.3748/wjg.v22.i26.5879

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach;Modern Pathology;2024-11

3. Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition;ESMO Open;2024-06

4. Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?;Exploration of Targeted Anti-tumor Therapy;2024-05-23

5. Tumor Budding, p53, and DNA Mismatch Repair Markers in Sinonasal Intestinal-Type Adenocarcinoma: A Retrospective Study Supports the Adverse Prognostic Impact of Tumor Budding;Cancers;2024-05-16